Categories
Tags
-
#COVID-19
#SARS-CoV-2
#IVD
#SARS-CoV-2 drugs
#Cross-reactivity
#Monoclonal antibody
#Antibody; activator and inhibitor
#SARS-CoV-2; Cytopathic Effect
#ADCC; antibody
#immunotherapy; cat
#Bispecific antibodies
#therapeutic human monoclonal antibodies
#TCR
#RP-HPLC
#immunoglobulins
#Fc-fusion protein
#cell-based bioassay
#Single Cell
#Ribosome
#Half-Life Extension
#Midbody Ring
#Asialoglycoprotein Receptor
#Exosome
#Microfluidic Health Monitoring
#Recombinant Immunotoxin
#Single-Cell
#Microfluidic Solutions
#Subunit Vaccine
#Polysome Profiling
#Half-life Assay
#humanized mouse model
#Rheumatoid Arthritis
#SARS-CoV-2 spike S1 domain
Archives
SARS-CoV-2 Subunit Vaccine service
-
Similar to other enveloped RNA viruses, SARS-CoV-2 has a trimeric spike
protein on its viral envelope. Since the trimeric S protein of SARS-CoV-2 is responsible for binding to the host cell surface receptor ACE2 and mediating subsequent viral entry, the trimeric S protein is a very attractive candidate for developing subunit vaccines. Creative Biolabs has an innovative vaccine development platform that allows the production of novel, covalently trimerized fusion proteins. With our unique vaccine development platform, we provide comprehensive SARS-CoV-2 S subunit vaccine development services, including gene synthesis, vector construction, protein expression and purification, immunoassay,etc.